News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pluristem Therapeutics (PSTI) Shares Slump A Day Before Phase 1/2 Study Results Are Released



1/20/2014 8:34:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The share price of Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR) fell by 19.5% in morning trading on the Tel Aviv Stock Exchange (TASE) today, before partly recovering, without any announcement from the company. The volatility in share price comes a day before the company publishes the results of a clinical trial of its stem cell treatment for muscle injury. Pluristem's share price was down 8.3% by early afternoon on the TASE today, to NIS 14.42, after falling 0.9% on Nasdaq on Friday to $4.43, giving a market cap of $265 million.

Help employers find you! Check out all the jobs and post your resume.

Read at Globes Online

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES